Northwest Biotherapeutics, Inc. Common stock
NWBO
NWBO was delisted on the 16th of December, 2016.
6 hedge funds and large institutions have $34K invested in Northwest Biotherapeutics, Inc. Common stock in 2018 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, reducing their positions, and closing their positions.
50% more funds holding
Funds holding: 4 → 6 (+2)
48% more capital invested
Capital invested by funds: $23K → $34K (+$11K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HNB
Huntington National Bank
Columbus,
Ohio
|
+$5K |
| 2 |
HAG
HighPoint Advisor Group
Downers Grove,
Illinois
|
+$4K |
Top Sellers
NWBO Hedge Fund Activity: Q4 2018 in Review
6 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q4 2018, worth a combined $34K — up 48% from $23K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new NWBO positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Huntington National Bank, opening a new position worth an estimated $5K.
- 6 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q4 2018, up from 4 in Q3 2018.
- Funds reported $34K of Northwest Biotherapeutics, Inc. Common stock stock for Q4 2018, up 48% quarter-over-quarter.
- 2 funds opened new Northwest Biotherapeutics, Inc. Common stock positions in Q4 2018 and 0 closed out, a net change of +2 holders.
- The largest Northwest Biotherapeutics, Inc. Common stock buyer in Q4 2018 was Huntington National Bank, an estimated $5K added.
Based on aggregated 13F filings for Q4 2018.